Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

類似資料

• Baseline and changes in inflammatory parameters for patients with EGFR‐mutated NSCLC treated with afatinib
  著者:: Zi‐Ting Chang, 等
  出版事項: (2025-07-01)
• Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study
  著者:: Qi-An Wang, 等
  出版事項: (2025-03-01)
• The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
  著者:: Hsu, Ping-Chih, 等
  出版事項: (2020)
• Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
  著者:: Yan-Jei Tang, 等
  出版事項: (2024-01-01)
• Real-World Efficacy and Safety of S-1 Monotherapy in Non-Small Cell Lung Cancer Management: Insights From a Multicenter Retrospective Cohort Study
  著者:: I-Lin Tsai, 等
  出版事項: (2025-06-01)